RPO Scientific

about RPO Scientific

The oncology market is complex, competitive, and subject to continuous change. When it comes to the research and development of new anti-cancer treatments, biopharmaceutical companies rely on the specific medical, scientific, and clinical knowledge and know-how of experts.

That's where RPO Scientific comes in. As an advisory body of experts, we hold the relevant multi-disciplinary expertise and experience to help advance the clinical development of theranostic agents in precision oncology. This means we support the research and development of the molecules required to create radiomolecular anti-cancer treatments, offer advice on speciality drug design, and facilitate clinical trials.

about RPO scientific

Development of
theranostic agents

We have the specific expertise to develop theranostic molecules for radiomolecular therapy and offer theranostic consulting to partners and clients.

Our services

Committed to clinical development

Our affiliated theranostic CRO - RPO Clinical - offers a complete range of clinical trial services in every step of the process.

RPO is all about the right chemistry - both between people and molecules. Building rapport with clients or coupling ligands with radionuclides: it’s the click that brings results. RPO combines an outstanding radiomolecular expertise, with a lean business model, select hospital network, robust diverse team, and transparant financials. Following gap analysis based on analytics & insights, RPO offers support on demand, on time and within budget.

Professor Dr Andrea Frilling MD, PhD, FACS, FRCS, FEBS

Professor of Surgery, Chair in Endocrine Surgery, Honorary Consultant Surgeon
Department of Surgery and Cancer, Imperial College, London, UK